Company: PTPI
Filing Date: 2025-02-21
Form Type: 8-K
Source: 0001104659-25-016181
Chunk: 1

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-21
Form: 8-K
Item: Item 1.01
Chunk 1
---

its reasonable best efforts to obtain such approval within 60 days from the closing of the Offering, and agreed to cause an additional
stockholder meeting to be held every 90 days thereafter until such Warrant Stockholder Approval is obtained.

Subject to certain limitations described in the
Pre-Funded Warrants, the Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal consideration of $0.0001 per
share any time until all of the Pre-Funded Warrants are exercised in full. A holder will not have the right to exercise any portion of
the Warrants or the Pre-Funded Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99%,
respectively (or at the election of the holder of the Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants or the Pre-Funded
Warrants, respectively. However, upon notice from the holder to the Company, the holder may increase the beneficial ownership limitation
pursuant to the Warrants, which may not exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants, provided that any increase in
the beneficial ownership limitation will not take effect until 61 days following notice to the Company.

The aggregate gross proceeds from the Offering
are approximately $9.6 million before deducting estimated offering expenses payable by the Company. The Company intends to use the net
proceeds from the offering for working capital and general corporate purposes.

Dawson James Securities, Inc. (“ Dawson”)
acted as the Company’s exclusive placement agent in connection with the Offering, pursuant to that certain engagement letter, dated
as of January 24, 2025, between the Company and Dawson (the “ Engagement Letter”). Pursuant to the Engagement Letter,
the Company agreed to pay Dawson a cash fee equal to 8.0% of the aggregate gross proceeds of the Offering, and reimbursed certain expenses
and legal fees.

The Units, the Pre-Funded Units, the Shares, the
Pre-Funded Warrants, the Warrants, the Warrant Shares and the Pre-Funded Warrant Shares were offered by the Company pursuant to a registration
statement on Form S